Startuoliai · 2026-10-271 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Vietinis automatinis vertimas · Pradinis šaltinio kalba
Summary
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Pradinis šaltinio kalba: PR Newswire UK — News ReleasesAtidaryti pirminį pranešimą →